M. Mateo

发表

Effects of Rilpivirine on Human Adipocyte Differentiation, Gene Expression, and Release of Adipokines and Cytokines

F. Villarroya, M. Giralt, P. Domingo, 2012, Antimicrobial Agents and Chemotherapy.

Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients

F. Villarroya, F. Vidal, M. Giralt, 2010, AIDS.

Relationship between HIV/Highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens.

F. Villarroya, M. Baiget, F. Vidal, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Uridine Metabolism in HIV-1-Infected Patients: Effect of Infection, of Antiretroviral Therapy and of HIV-1/ART-Associated Lipodystrophy Syndrome

F. Villarroya, A. Andreu, F. Vidal, 2010, PloS one.

Association of ITPA Gene Polymorphisms and the Risk of Ribavirin-Induced Anemia in HIV/Hepatitis C Virus (HCV)-Coinfected Patients Receiving HCV Combination Therapy

M. Baiget, F. Vidal, P. Domingo, 2012, Antimicrobial Agents and Chemotherapy.

Does choice of antiretroviral drugs matter for inflammation?

F. Vidal, P. Domingo, M. Mateo, 2019, Expert review of clinical pharmacology.

An update on the pharmacological strategies in the treatment of HIV-1-associated adipose redistribution syndromes

F. Vidal, P. Domingo, M. Mateo, 2014, Expert opinion on pharmacotherapy.

Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines.

F. Villarroya, M. Giralt, P. Domingo, 2010, Current HIV research.

Effects of docosahexanoic acid supplementation on inflammatory and subcutaneous adipose tissue gene expression in HIV‐infected patients on combination antiretroviral therapy (cART). A sub‐study of a randomized, double‐blind, placebo‐controlled study

F. Villarroya, F. Vidal, J. Villarroya, 2018, Cytokine.

Reduced Levels of Serum FGF19 and Impaired Expression of Receptors for Endocrine FGFs in Adipose Tissue From HIV-Infected Patients

F. Villarroya, F. Vidal, M. Giralt, 2012, Journal of acquired immune deficiency syndromes.

The Molecular Signature of HIV-1-Associated Lipomatosis Reveals Differential Involvement of Brown and Beige/Brite Adipocyte Cell Lineages

F. Villarroya, E. Martinez, J. Villarroya, 2015, PloS one.

High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patients.

F. Villarroya, F. Vidal, J. Villarroya, 2017, Metabolism: clinical and experimental.

Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines.

F. Villarroya, J. Villarroya, M. Giralt, 2016, Antiviral research.

Drug safety profile of integrase strand transfer inhibitors

F. Vidal, P. Domingo, M. Mateo, 2014, Expert opinion on drug safety.

Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection

F. Vidal, P. Domingo, M. Mateo, 2012, Expert opinion on drug safety.

Simpliﬁcation to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients

D. Podzamczer, J. Navarro, A. Curran, 2012 .

Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy

P. Domingo, M. Mateo, M. Gutiérrez, 2011, Expert review of endocrinology & metabolism.

Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study

Miguel Ángel Martínez, D. Podzamczer, J. Mallolas, 2021, The Lancet HIV.

Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH)

F. Vidal, P. Domingo, M. Mateo, 2021, Expert opinion on pharmacotherapy.

Association of Thymidylate Synthase Polymorphisms with Acute Pancreatitis and/or Peripheral Neuropathy in HIV-Infected Patients on Stavudine-Based Therapy

F. Villarroya, E. Martinez, M. Baiget, 2013, PloS one.

Association of Thymidylate Synthase Gene Polymorphisms with Stavudine Triphosphate Intracellular Levels and Lipodystrophy

F. Villarroya, M. Baiget, F. Vidal, 2011, Antimicrobial Agents and Chemotherapy.

Barriers to health care services for migrants living with HIV in Spain

J. Miro, B. Ledergerber, E. Fernández, 2018, European journal of public health.

The toxicogenetics of antiretroviral therapy: the evil inside.

F. Vidal, P. Domingo, M. Mateo, 2011, Current medicinal chemistry.

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DU

D. Podzamczer, B. Clotet, E. Negredo, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Circulating fibroblast growth factor 23 (FGF23) levels are associated with metabolic disturbances and fat distribution but not cardiovascular risk in HIV-infected patients.

F. Villarroya, F. Vidal, J. Villarroya, 2015, The Journal of antimicrobial chemotherapy.

Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.

R. Paredes, D. Podzamczer, B. Clotet, 2021, The lancet. HIV.

Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV/AIDS

F. Vidal, P. Domingo, M. Mateo, 2013, Expert opinion on pharmacotherapy.

Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping.

R. Paredes, D. Podzamczer, M. Noguera-Julián, 2020, The Journal of antimicrobial chemotherapy.

Drug-drug interactions when treating HIV-related metabolic disorders

F. Vidal, P. Domingo, M. Mateo, 2019, Expert opinion on drug metabolism & toxicology.

Tolerability of Current Antiretroviral Single-Tablet Regimens

F. Vidal, P. Domingo, M. Mateo, 2019, AIDS Reviews.

Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B*40∶01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients

F. Villarroya, M. Baiget, F. Vidal, 2013, PloS one.

A 48-Week Study of Fat Molecular Alterations in HIV Naive Patients Starting Tenofovir/Emtricitabine With Lopinavir/Ritonavir or Efavirenz

F. Villarroya, F. Vidal, J. Villarroya, 2014, Journal of acquired immune deficiency syndromes.

Effects of docosahexanoic acid on metabolic and fat parameters in HIV-infected patients on cART: A randomized, double-blind, placebo-controlled study.

F. Villarroya, F. Vidal, J. Villarroya, 2017, Clinical nutrition.

Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy

F. Villarroya, F. Vidal, J. Villarroya, 2022, Journal of clinical medicine.

Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial.

Maria-Silvana Di Yacovo, D. Podzamczer, B. Clotet, 2014, The Journal of antimicrobial chemotherapy.

Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.

Manuel Crespo, D. Podzamczer, J. Navarro, 2012, The Journal of antimicrobial chemotherapy.

Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen.

D. Podzamczer, A. Curran, J. Burgos, 2012, The Journal of antimicrobial chemotherapy.

Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes.

T. Quesada-López, F. Villarroya, J. Villarroya, 2022, Life sciences.